Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors
Science Advances · 12.09.2025 · 11 (37)
DOI: 10.1126/sciadv.adz8980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 12.09.2025. Verfasst von Yuta Hikichi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Integrase Inhibitors, Drug Resistance, Viral, Mutation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Persons with HIV (PWH) receiving integrase (IN) strand transfer inhibitors (INSTIs) have been reported to experience virologic failure (VF) in the absence of resistance mutations in IN. We previously reported that mutations in the viral nucleocapsid (NC) are selected in the presence of the INSTI dolutegravir (DTG). Here, we show that these NC mutations accelerate the kinetics of viral DNA integration, suggesting that they limit the window of time available for INSTIs to block viral DNA integration. We find that in primary peripheral blood mononuclear cells, HIV-1 acquires mutations in the viral envelope glycoprotein, NC, and occasionally IN during selection for INSTI resistance. Notably, the selected NC and IN mutations act in concert to reduce the susceptibility of the virus to INSTIs. These results provide insights into the mechanism by which HIV-1 escapes the inhibitory activity of INSTIs and underscore the importance of genotypic analysis outside IN in PWH experiencing VF on INSTI-containing drug regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
- Viral Mutation Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
- Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
ORCID-Profile: Yuta Hikichi, Ryan C Burdick, Sean C Patro, Si-Yuan Ding, Brian T Luke, Erin D Clark, Sherimay D Ablan, Xiaolin Wu, Vinay K Pathak, Eric O Freed
Förderung
- NIAID NIH HHS
Zitieren
APA
Hikichi, Y., Burdick, R. C., Patro, S. C., Ding, S. Y., Luke, B. T., Clark, E. D., Ablan, S. D., Wu, X., Pathak, V. K., & Freed, E. O. (2025). Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors. Science Advances, 11(37). https://doi.org/10.1126/sciadv.adz8980
Vancouver
Hikichi Y, Burdick RC, Patro SC, Ding SY, Luke BT, Clark ED, et al. Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors. Science Advances. 2025;11(37). doi:10.1126/sciadv.adz8980
BibTeX
@article{Hikichi2025,
author = {Hikichi, Yuta and Burdick, Ryan C and Patro, Sean C and Ding, Si-Yuan and Luke, Brian T and Clark, Erin D and Ablan, Sherimay D and Wu, Xiaolin and Pathak, Vinay K and Freed, Eric O},
title = {Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {37},
doi = {10.1126/sciadv.adz8980}
}
EUVIMED